SEMA5A

Across TCGA pan-cancer cohorts, SEMA5A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEMA5A data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEMA5A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEMA5A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SEMA5A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.373	0.824	<.001	34	view →
LUAD	OS	Tertile	II,III,IV	0.429	0.860	.014	23	view →
CCRCC	OS	Median	III,IV	0.854	0.539	.004	19	view →
LSCC	OS	Quartile	III,IV	0.918	0.536	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SEMA5A–PDAC (OS)

Open the PDAC breakdown →